16,525 Shares in Assembly Biosciences Inc (ASMB) Acquired by Mackenzie Financial Corp
Mackenzie Financial Corp bought a new stake in Assembly Biosciences Inc (NASDAQ:ASMB) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm bought 16,525 shares of the biopharmaceutical company’s stock, valued at approximately $577,000. Mackenzie Financial Corp owned approximately 0.08% of Assembly Biosciences at the end of the most recent reporting period.
Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Vanguard Group Inc. increased its holdings in shares of Assembly Biosciences by 11.2% in the first quarter. Vanguard Group Inc. now owns 503,851 shares of the biopharmaceutical company’s stock valued at $12,843,000 after purchasing an additional 50,615 shares during the last quarter. Strs Ohio increased its holdings in shares of Assembly Biosciences by 66.9% in the third quarter. Strs Ohio now owns 22,700 shares of the biopharmaceutical company’s stock valued at $792,000 after purchasing an additional 9,100 shares during the last quarter. AXA acquired a new stake in shares of Assembly Biosciences in the second quarter valued at approximately $2,477,000. California Public Employees Retirement System increased its holdings in shares of Assembly Biosciences by 118.3% in the second quarter. California Public Employees Retirement System now owns 24,540 shares of the biopharmaceutical company’s stock valued at $507,000 after purchasing an additional 13,300 shares during the last quarter. Finally, JPMorgan Chase & Co. acquired a new stake in shares of Assembly Biosciences in the second quarter valued at approximately $3,426,000. Institutional investors and hedge funds own 62.09% of the company’s stock.
In other Assembly Biosciences news, Director William R. Ringo sold 1,000 shares of the firm’s stock in a transaction on Friday, December 1st. The stock was sold at an average price of $49.37, for a total transaction of $49,370.00. Following the completion of the sale, the director now owns 20,465 shares of the company’s stock, valued at $1,010,357.05. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. In the last three months, insiders have sold 3,000 shares of company stock valued at $112,620. 19.60% of the stock is owned by insiders.
Shares of Assembly Biosciences Inc (NASDAQ:ASMB) opened at $43.99 on Tuesday. Assembly Biosciences Inc has a one year low of $11.07 and a one year high of $52.37.
Several equities research analysts recently commented on the company. Chardan Capital reaffirmed a “buy” rating on shares of Assembly Biosciences in a report on Sunday, September 17th. Zacks Investment Research raised Assembly Biosciences from a “hold” rating to a “buy” rating and set a $37.00 target price for the company in a research note on Wednesday, November 15th. ValuEngine cut Assembly Biosciences from a “hold” rating to a “sell” rating in a research note on Thursday, December 7th. BidaskClub raised Assembly Biosciences from a “buy” rating to a “strong-buy” rating in a research note on Thursday, August 24th. Finally, Jefferies Group started coverage on Assembly Biosciences in a research note on Wednesday, November 8th. They set a “buy” rating and a $50.00 target price for the company. One analyst has rated the stock with a sell rating and four have issued a buy rating to the stock. The company has a consensus rating of “Buy” and an average price target of $40.67.
WARNING: This piece was originally posted by Daily Political and is owned by of Daily Political. If you are accessing this piece on another site, it was stolen and republished in violation of international copyright & trademark laws. The legal version of this piece can be viewed at https://www.dailypolitical.com/2017/12/12/16525-shares-in-assembly-biosciences-inc-asmb-acquired-by-mackenzie-financial-corp.html.
About Assembly Biosciences
Assembly Biosciences, Inc is a biotechnology company. The Company is engaged in developing two platform programs, such as a class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection, and a class of oral synthetic live therapeutics, which are designed to restore health to a dysbiotic microbiome.
Want to see what other hedge funds are holding ASMB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Assembly Biosciences Inc (NASDAQ:ASMB).
Receive News & Ratings for Assembly Biosciences Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Assembly Biosciences Inc and related companies with MarketBeat.com's FREE daily email newsletter.